Insider Insights
01.02.2022
NICEs new methods and processes manual

The National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...

Read more
Insider Insights
01.02.2022
Prescribing controls on new medicines

The Ministry of Health reports that 65.1% of medicines admitted to reimbursement in 2021 were subjec...

Read more
Articles
27.01.2022
Early access schemes in France

The 2021 Social Security Law made provision for overhauling the early scheme in France. As of 1st Ju...

Read more
Articles
25.01.2022
PMA Perspectives Q1 2022

We hope you’ve had a wonderful start to the New Year and we’d love to welcome you to our fourth ...

Read more
Articles
20.01.2022
Orphan drugs market access

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo a r...

Read more
Articles
17.01.2022
COVID-19 Two Year Review

As we enter 2022, we are approaching the two-year anniversary of the COVID-19 pandemic spreading acr...

Read more
Articles
10.01.2022
Conducting a HTA review

Reviewing previous HTA submissions can provide valuable insights that can help manufacturers prepare...

Read more
Articles
05.01.2022
Orphan Drugs and Diseases: 101

This article discusses updates to the orphan drugs and diseases landscapes, the challenges and incen...

Read more
Articles
20.12.2021
The end of higher drug prices in the US

In the US, an Act recently passed through the House of Representatives which plans to expand afforda...

Read more
Articles
15.12.2021
Patent protection in the pharmaceutical industry

Patent cliff refers to a sharp decline in revenue or profitability when a firm’s patents expire, o...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.